454 related articles for article (PubMed ID: 36004812)
21. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
[TBL] [Abstract][Full Text] [Related]
22. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
23. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
24. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
25. Target Validation Using PROTACs: Applying the Four Pillars Framework.
Nowak RP; Jones LH
SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
27. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
28. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines.
Zhai J; Li C; Sun B; Wang S; Cui Y; Gao Q; Sang F
Bioorg Med Chem Lett; 2022 Dec; 78():129041. PubMed ID: 36332882
[TBL] [Abstract][Full Text] [Related]
30. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
31. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
32. New Frontiers in the Discovery and Development of PROTACs.
Barghout SH
Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
[TBL] [Abstract][Full Text] [Related]
33. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
[TBL] [Abstract][Full Text] [Related]
34. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
35. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
Qin L; Dai H; Wang J
Front Chem; 2022; 10():934337. PubMed ID: 35978859
[TBL] [Abstract][Full Text] [Related]
36. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Hu Z; Crews CM
Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
[TBL] [Abstract][Full Text] [Related]
37. Nano-PROTACs: state of the art and perspectives.
Zhong J; Zhao R; Wang Y; Su YX; Lan X
Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
[TBL] [Abstract][Full Text] [Related]
38. Chemistries of bifunctional PROTAC degraders.
Cao C; He M; Wang L; He Y; Rao Y
Chem Soc Rev; 2022 Aug; 51(16):7066-7114. PubMed ID: 35916511
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
40. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]